Left ventricular dysfunction following myocardial infarction

Active Ingredient: Carvedilol

Indication for Carvedilol

Population group: only adults (18 years old or older)
Therapeutic intent: Curative procedure

Carvedilol is indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of less than or equal to 40% (with or without symptomatic heart failure).

For this indication, competent medicine agencies globally authorize below treatments:

6.25 mg twice daily for 3-10 days, and then increased to 12.5 mg twice daily based on tolerability, and then again to the target dose of 25 mg twice daily

For:

Dosage regimens

Oral, 6.25 milligrams carvedilol, 2 times daily to meals, over the duration of 3 to 10 days. Afterwards, oral, 12.5 milligrams carvedilol, 2 times daily to meals, over the duration of 3 to 10 days. Afterwards, oral, 25 milligrams carvedilol, 2 times daily to meals. The maximum allowed total dose is 50 milligrams carvedilol daily.

Detailed description

DOSAGE MUST BE INDIVIDUALIZED AND MONITORED DURING UP-TITRATION. Treatment with carvedilol may be started as an inpatient or outpatient and should be started after the patient is hemodynamically stable and fluid retention has been minimized.

It is recommended that carvedilol be started at 6.25 mg twice daily and increased after 3 to 10 days, based on tolerability, to 12.5 mg twice daily, then again to the target dose of 25 mg twice daily. A lower starting dose may be used (3.125 mg twice daily) and/or the rate of up-titration may be slowed if clinically indicated (e.g., due to low blood pressure or heart rate, or fluid retention). Patients should be maintained on lower doses if higher doses are not tolerated. The recommended dosing regimen need not be altered in patients who received treatment with an IV or oral β-blocker during the acute phase of the myocardial infarction.

Dosage considerations

It should be taken with food to slow the rate of absorption and reduce the incidence of orthostatic effects.

Active ingredient

Carvedilol

Carvedilol is a vasodilatory non-selective beta-blocker, which reduces the peripheral vascular resistance by selective alpha1-receptor blockade and suppresses the renin-angiotensin system through non-selective beta-blockade. Plasma renin activity is reduced and fluid retention is rare.

Read more about Carvedilol

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.